<DOC>
	<DOC>NCT02946671</DOC>
	<brief_summary>To assess the safety of preoperative combination therapy with KW-0761 (anti-CCR4) and ONO-4538 (anti-PD-1). To assess the behavior of immune cells in peripheral blood and tumor.</brief_summary>
	<brief_title>Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients who enable to have standard operation Patients who refuse standard preoperative chemotherapy and are diagnosed with following cancers; gastric adenocarcinoma, esophageal squamous cell carcinoma, nonsmallcell lung carcinoma or renal cell carcinoma Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Patients with no serious disorder of major organs (born marrow, heart, lung, liver and kidney) Patients with written informed consent Patients who have measurable target lesion Patients who are enable to undergo biopsy for sampling tumor tissue Known or previous autoimmune disease Known or suspected interstitial lung disease (ILD) Patients with history of serious anaphylaxis induced by antibody preparation Uncontrollable hypertension Uncontrollable endocrine disease Patients who have active inflammatory bowel disease or other serious GI chronic conditions associated with diarrhea Uncontrollable diabetes Prior therapy with sustained anticancer agents, radiotherapy or surgery for primary disease Pregnant or lactating females, female and male patients who cannot agree to practice the adequate birth control after the consent during the study Known or suspected infection or inflammatory disease Prior therapy with hematopoietic stem cell transplantation Known or suspected central nervous system (CNS) involvement</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>